1. European Medicines Agency . Fycompa® Annex I: Summary of Product Characteristics, July 2020. Available at: https://www.ema.europa.eu/en/documents/product-information/fycompa-epar-product-information_en.pdf. Accessed November 26, 2020.
Google Scholar2. Food and Drug Administration . Fycompa® Prescribing Information, September 2020. Available at: https://www.fycompa.com/-/media/Files/Fycompa/Fycompa_Prescribing_Information.pdf. Accessed November 26, 2020.
Google Scholar3. French, JA, Krauss, GL, Biton, V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012;79(6):589-596.
Google Scholar | Crossref | Medline4. French, JA, Krauss, GL, Steinhoff, BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54(1):117-125.
Google Scholar | Crossref | Medline5. Krauss, GL, Serratosa, JM, Villanueva, V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;78(18):1408-1415.
Google Scholar | Crossref | Medline6. Nishida, T, Lee, SK, Inoue, Y, Saeki, K, Ishikawa, K, Kaneko, S. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study. Acta Neurol Scand. 2018;137(4):392-399.
Google Scholar | Crossref | Medline7. French, JA, Krauss, GL, Wechsler, RT, et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: a randomized trial. Neurology. 2015;85(11):950-957.
Google Scholar | Crossref | Medline8. Flamini, R, Patten, A, Ngo, LY. Long-term safety and efficacy of adjunctive perampanel in pediatric patients (aged 4 to <12 years) with partial-onset seizures or primary generalized tonic-clonic seizures in Study 311. Poster 007. Poster presented at: the 72nd Annual Meeting of the American Academy of Neurology, Toronto, Canada, May 2020.
Google Scholar9. Piña-Garza, JE, Rosenfeld, W, Saeki, K, et al. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: post hoc analysis of six randomized studies. Epilepsy Behav. 2020;104(Pt A): 106876.
Google Scholar | Crossref | Medline10. Krauss, GL, Perucca, E, Ben-Menachem, E, et al. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307. Epilepsia. 2014;55(7): 1058-1068.
Google Scholar | Crossref | Medline11. Clinicaltrials.gov . A efficacy and safety study of adjunctive perampanel in primary generalized tonic clonic seizures [updated August 28, 2017]. Available at: https://www.clinicaltrials.gov/ct2/show/NCT01393743. Accessed November 26, 2020.
Google Scholar12. Piña-Garza, JE, Lagae, L, Villanueva, V, et al. Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures. Epilepsy Behav. 2018;83: 50-58.
Google Scholar | Crossref | Medline13. Renfroe, JB, Mintz, M, Davis, R, et al. Adjunctive perampanel oral suspension in pediatric patients from >/=2 to <12 years of age with epilepsy: pharmacokinetics, safety, tolerability, and efficacy. J Child Neurol. 2019;34(5): 284-294.
Google Scholar | SAGE Journals | ISI14. Makady, A, de Boer, A, Hillege, H, Klungel, O, Goettsch, W. What is real-world data? A review of definitions based on literature and stakeholder interviews. Value Health. 2017;20(7):858-865.
Google Scholar | Crossref | Medline15. French, JA . Trial design: how do we figure out if an AED works. Epilepsy Curr. 2012;12(1): 24-26.
Google Scholar | SAGE Journals16. Wechsler, RT, Wheless, J, Lancman, M, Aboumatar, S, Patten, A, Malhotra, M. Perampanel in real-world clinical care of patients with epilepsy: retrospective phase IV PROVE Study 506. Poster 22. Poster presented at the 12th International Epilepsy Colloquium, Lyon, France, 26–28 May 2019.
Google Scholar17. Segal, E, Wheless, J, Moretz, K, Penovich, P, Patten, A, Malhotra, M. PROVE Study 506 – a Retrospective, Phase IV Study of Perampanel in Real-World Clinical Care of Patients with Epilepsy: Adolescent Subgroup (Aged 12 to <18 Years). Poster 23. Poster presented at the 12th International Epilepsy Colloquium, Lyon, France, 26-28 May 2019.
Google Scholar18. Brandt, C, Wechsler, RT, O’Brien, TJ, et al. Adjunctive perampanel and myoclonic and absence seizures: post hoc analysis of data from study 332 in patients with idiopathic generalized epilepsy. Seizure. 2020;80: 115-123.
Google Scholar | Crossref | Medline19. Ettinger, AB, LoPresti, A, Yang, H, et al. Psychiatric and behavioural adverse events in randomized clinical studies of the noncompetetive AMPA receptor antagonist perampanel. Epilepsia. 2015;56(8): 1252-1263.
Google Scholar | Crossref | Medline